National Healthcare's 15-min chart shows MACD and KDJ death crosses.

National Healthcare's 15-minute chart recently exhibited a MACD Death Cross and KDJ Death Cross on August 28, 2025 at 09:45. This signals a potential continuation of the downward trend in the stock price, as the momentum is shifting towards the downside. Consequently, there is a high likelihood of further decreases in the stock price.

China's recent policy signals have boosted the confidence of foreign pharmaceutical companies in the country's robust pharmaceutical ecosystem. A senior executive from AstraZeneca China, Hu Yiqing, highlighted the positive impact of Premier Li Qiang's recent urging for more effective guidance in the application of high-quality, innovative medicines [1]. Hu expressed optimism that this vision could translate into concrete policies that would aid in the development of innovative drugs.

Hu Yiqing, vice-president of AstraZeneca China and head of its rare diseases business unit, noted that the country has a robust pipeline of nearly 10 new rare disease products or indications set to hit the market in the next five years. He called for further strengthening of support mechanisms, including enhancing rare disease screening programs and ensuring broader insurance coverage for these often-costly treatments.

China's medical insurance spending on innovative drugs has grown significantly, increasing by 40 percent annually. By 2024, related spending reached 3.9 times the amount recorded in 2020, according to data from the National Healthcare Security Administration [1].

The potential of China's rare disease landscape for global pharmaceutical companies is substantial. By leveraging the innovative mindset of Chinese expertise and the large patient population, companies can gain valuable insights to strengthen their global pipelines. Hu Yiqing emphasized that while Chinese experts are currently participating in international phase-3 clinical trials, they are expected to progress to leading their own investigator-initiated trials and ultimately spearhead global R&D efforts in innovative rare disease drugs [1].

China's pharmaceutical industry is now the second largest in the world, accounting for about 30 percent of the global total of innovative drugs in research, as stated by Yang Sheng, deputy head of the National Medical Products Administration [1].

References:
[1] https://www.chinadaily.com.cn/a/202508/26/WS68ad8262a3108622abc9d41e.html